Compare ATYR & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATYR | COCH |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 51.0M |
| IPO Year | 2015 | 2021 |
| Metric | ATYR | COCH |
|---|---|---|
| Price | $0.36 | $0.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | $3.67 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 728.9K | 49.4K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.98 | ★ 17.45 |
| EPS | N/A | ★ N/A |
| Revenue | $190,000.00 | ★ $241,000.00 |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $0.37 | $0.36 |
| 52 Week High | $1.12 | $1.89 |
| Indicator | ATYR | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 25.85 | 42.99 |
| Support Level | N/A | $0.63 |
| Resistance Level | $0.59 | $0.74 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 2.13 | 11.33 |
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.